Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.38M Buy
22,458
+6,649
+42% +$754K 0.01% 826
2025
Q4
$1.59M Sell
15,809
-22,120
-58% -$2.4M 0.01% 973
2025
Q3
$4.68M Buy
37,929
+1,302
+4% +$162K 0.03% 447
2025
Q2
$4.4M Buy
36,627
+12,817
+54% +$1.71M 0.03% 403
2025
Q1
$3.5M Buy
23,810
+974
+4% +$149K 0.04% 379
2024
Q4
$3.72M Buy
22,836
+14,397
+171% +$2.36M 0.04% 338
2024
Q3
$1.36M Buy
8,439
+5,946
+239% +$881K 0.03% 454
2024
Q2
$340K Buy
+2,493
New +$346K 0.01% 670

Other funds holding CLX

&Partners's CLX Position: Q1 2026 in Review

&Partners increased its Clorox (CLX) stake by 42% in Q1 2026, buying an estimated $754K and bringing the position to 22,458 shares worth $2.38M. The position accounts for 0.01% of the portfolio, ranked #826.

&Partners first reported a position in CLX in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.68M in Q3 2025. 1,080 funds tracked by Wall St. Rank hold CLX as of Q1 2026.

  • &Partners held 22,458 shares of Clorox worth $2.38M as of Q1 2026.
  • &Partners bought 6,649 Clorox shares in Q1 2026, an estimated $754K.
  • Clorox made up 0.01% of &Partners's portfolio in Q1 2026, its #826 holding.
  • &Partners first reported a position in Clorox in Q2 2024 and has held it in 8 quarters since.
  • &Partners's Clorox position peaked at $4.68M in Q3 2025.
  • 1,080 funds tracked by Wall St. Rank held Clorox as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.